InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
61,435.91
(
0.89%
)
Post# of 252431
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Bickema

Send PM Follow Ignore
Followers 20
Posts 1631
Boards Moderated 0
Alias Born 11/10/2010

Bickema

Re: None

Tuesday, 06/30/2015 9:37:13 AM

Tuesday, June 30, 2015 9:37:13 AM

Post# of 252431
AbbVie (NYSE:ABBV) shares ended sharply lower on Monday but the company has something to cheer. It is gaining some traction in the hep C space. According to data from Symphony Health and Bloomberg, AbbVie saw an 8.8% increase in total prescription volumes for its hep C drug Viekira Pak for the week ended June 19th. Total prescription volumes for Gilead Sciences' (NASDAQ:GILD) Harvoni and Sovaldi declined 5% and 10.5%, respectively. While AbbVie remains significantly behind Gilead in the hep C space, the company did have some positive news to share last week.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up